Table 1.
Clinical trials using anti-angiogenesis agents for ovarian cancer
| Study | Drug | Stage | Population | n | Arm | PFS | OS | ORR(%) | ORR(%) | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| months | HR (95% CI) | months | HR (95% CI) | ||||||||
| G0218 (Burger et al, 2013)47 | BEV | III/IV | Primary,maintain | 1873 | A:BEV + CP→ BEV B:PL + CP→ PL | 14.1 vs 10.3 | 0.77 (0.68–0.87) | 39.7 vs 39.3 | 0.885 (0.775–1.04) | 74 vs 52 | 74 vs 52 |
| ICON7 (Stark et al, 2013)48 | BEV | I-IV | Primary, maintain | 1528 | A:BEV+CP→ BEV B:CP | 19.98 vs 17.4 | 0.93 (0.83–1.05) | 58 vs 58.6 | 0.99 (0.85–1.14) | 67 vs 48 | 67vs48 |
| GOG0213 (Husain et al, 2016)49 | BEV | NR | Recurrent, platinum-sensitive | 674 | A:CP B: BEV+CP→ BEV |
10.4 vs 13.8 | 0.614（0.522–0.722） | 37.3 vs 42.2 | 0.827 (0.683–1.005) | 58.4 vs 78.8 | 58.4vs78.8 |
| OCEANS (Aghajanian et al, 2012; Aghajanian et al, 2015)50,51 | BEV | NR | Recurrent, platinum-sensitive | 484 | A:BEV+CG→ BEV B:PL+CG→PL | 12.4 vs 8.4 | 0.484 (0.388–0.605) | 33.4 vs 33.7 | 0.96 (0.76–1.2) | 78.5 vs 57.4 | 78.5 vs 57.4 |
| AURELIA (Pujade-Lauraine et al, 2014)52 | BEV | NR | Recurrent, platinum-resistant | 361 | A:BEV+CT B:CT | 6.7 vs 3.4 | 0.48 (0.38–0.60) | 16.6 vs 13.3 | 0.85（0.66–1.08） | 27.3 vs 11.8 | 27.3vs11.8 |
| ICON6 (Ledermann et al, 2016)31 | cediranib | NR | Recurrent, platinum-sensitive | 456 | A:PL+CT→ PL B:cediranib+CT→cediranib | 8.7 vs 11.0 | 0.56 (0.44–0.72) | 21.0 vs 26.3 | 0.77 (0.55–1.07) | NR | NR |
| TRIAS (Chekerov et al, 2018)5 | sorafenib | NR | Recurrent, platinum-resistant | 172 | A:topotecan+ sorafenib B: topotecan + PL | 6.7 vs 4.4 | 0.60 (0.43–0.83) | 17.1 vs 10.1 | 0.65 (0.45–0.93) | 31 vs 12 | 31vs12 |
| MITO 11 (Pignata et al, 2015)33 | pazopanib | Ic-IV | Recurrent, platinum-resistant | 73 | A:P+ pazopanib B: P | 6.35 vs 3.49 | 0.42 (0.25–0.69) | 19.1 vs 13.7 | 0.60 (0.32–1.13) | 56 vs 25 | 56vs25 |
| NCT00710762 (Ledermann et al, 2011)30 | nintedanib | I-IV | Recurrent | 83 | A:CT→nintedanib B:CT→PL | NR | 0.65 (0.42–1.02) | NR | 0.84 (0.51–1.39) | NR | NR |
| SWOG S0904 (Coleman et al, 2014)53 | vandetanib | NR | Recurrent | 129 | A: D+ vandetanib B: D | 3.0 vs 3.5 | 0.99 (0.69–1.42) | 14 vs 18 | 1.25 (0.93–1.68)* | NR | NR |
| A Phase II study by Mial et al (Miao et al, 2018)40 | apatinib | NR | Recurrent platinum-resistant | 29 | apatinib monotherapy | 5.1 (3.8–6.5) | NR | 14.5 | 12.4–16.4 | 41.4 | 41.4 |
| AEROC (Lan et al, 2018)41 | apatinib | NR | Recurrent, platinum-resistant | 35 | apatinib+etoposide | 8.1 (2.8–13.4) | NR | NR | NR | 19 | 19 |
Note: *80% CI was used here.
Abbreviations: PFS, progression-free survival time; OS, overall survival; HR, hazard radio; ORR, objective response; CI, confidence interval; BEV, bevacizumab; C, carboplatin; P, paclitaxel; D, docetaxel; PL, placebo, G, gemcitabine; CT, chemotherapy; CP, carboplatin plus paclitaxel; CG, carboplatin plus gemcitabine; NR, not research.